Filing Flows › Journey Medical (DERM) › Q1 2026 › vs Q4 2025
Journey Medical (DERM) Q1 2026 vs Q4 2025 (quarter over quarter)
Journey Medical's revenue fell $118K (-0.7%) from $16.1M in Q4 2025 to $16.0M in Q1 2026. The biggest changes: Emrosi +$1.3M (+25%); Foam franchise products (Amzeeq & Zilxi) −$836K (-44%); Qbrexza −$516K (-9%).
Journey Medical, Q1 2026: revenue $16.0M (+22% year over year), operating margin -9.3%, net loss $2.2M, operating cash flow $2.9M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Emrosi | $6.3M | $5.0M | $1.3M | +25% |
| Qbrexza | $5.0M | $5.5M | −$516K | -9% |
| Accutane | $3.3M | $3.1M | $250K | +8% |
| Foam franchise products (Amzeeq & Zilxi) | $1.1M | $1.9M | −$836K | -44% |
| Other / legacy | $277K | $575K | −$298K | -52% |
| Revenue | $16.0M | $16.1M | −$118K | -0.7% |
| Net loss | $2.2M | $1.2M | $983K | +79% |
| Costs & expenses | $18.2M | $17.3M | $865K | +5% |
| Operating costs | $17.5M | $16.5M | $931K | +6% |
| Interest & other, net | $738K | $804K | −$66K | -8% |
| Cost of revenue | $6.2M | $5.4M | $778K | +14% |
| SG&A | $10.1M | $9.9M | $246K | +2% |
| Other operating costs | $1.1M | $1.1M | $61K | +6% |
| Operating cash sources | $5.1M | −$5.0M | $10.2M | — |
| Share-based compensation | $989K | $1.8M | −$786K | -44% |
| Working capital & other | $4.2M | −$6.8M | $11.0M | — |
| Net loss absorbed | $2.2M | $1.2M | $983K | +79% |
| Operating cash flow | $2.9M | −$6.3M | $9.2M | — |
Questions
How much did Journey Medical's revenue grow quarter over quarter in Q1 2026?
Journey Medical's revenue fell $118K (-0.7%) from $16.1M in Q4 2025 to $16.0M in Q1 2026.
What drove Journey Medical's revenue change in Q1 2026?
Emrosi +$1.3M (+25%); Foam franchise products (Amzeeq & Zilxi) −$836K (-44%); Qbrexza −$516K (-9%).